FDA places partial clinical hold on Zentalis’ trials of azenosertib for cancer

The US Food and Drug Administration (FDA) has placed a partial hold on three of the clinical studies of Zentalis Pharmaceuticals’ azenosertib, aimed at treating different types of cancer.